{
    "clinical_study": {
        "@rank": "20128", 
        "arm_group": {
            "arm_group_label": "Long-term follow up", 
            "arm_group_type": "Other", 
            "description": "Long-term follow up of patients who received UshStat in a previous study"
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to examine the long-term safety of an experimental gene transfer\n      agent UshStat, designed to treat retinitis pigmentosa associated with Ushers Syndrome Type\n      1b."
        }, 
        "brief_title": "A Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat\u00ae in Patients With Usher Syndrome Type 1B", 
        "completion_date": {
            "#text": "January 2032", 
            "@type": "Anticipated"
        }, 
        "condition": "Usher Syndrome Type 1b", 
        "condition_browse": {
            "mesh_term": "Usher Syndromes"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Must have been enrolled in Protocol US1/001/10\n\n          -  Must have received a subretinal injection of UshStat\u00ae\n\n        Exclusion Criteria:\n\n          -  Did not receive UshStat\u00ae as part of the US1/001/10 protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "18", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065011", 
            "org_study_id": "US1/002/13"
        }, 
        "intervention": {
            "arm_group_label": "Long-term follow up", 
            "description": "Long-term follow up of patients who received UshStat in a previous study", 
            "intervention_name": "UshStat", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239-4197"
                }, 
                "name": "Oregon Health & Science University"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Study to Determine the Long-Term Safety, Tolerability and Biological Activity of UshStat\u00ae in Patients With Usher Syndrome Type 1B", 
        "overall_official": {
            "affiliation": "Casey Eye Institute, Portland Oregon", 
            "last_name": "Richard Weleber, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "January 2032", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The number and percentage of patients with treatment emergent adverse events.", 
            "measure": "The incidence of adverse events.", 
            "safety_issue": "Yes", 
            "time_frame": "15 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065011"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Biological Activity: To determine a delay in retinal degeneration following subretinal injection of UshStat\u00ae, through changes in function relative to the untreated contralateral eye utilising retinal analytical techniques", 
            "measure": "Determine delay in retinal degeneration", 
            "safety_issue": "No", 
            "time_frame": "15 years"
        }, 
        "source": "Oxford BioMedica", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxford BioMedica", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}